A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Trial Profile

A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs SAR 366234 (Primary) ; Latanoprost
  • Indications Open-angle glaucoma
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
    • 13 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top